Ligand and structure based pharmacophore modeling to facilitate novel histone deacetylase 8 inhibitor design
- PMID: 20656379
- DOI: 10.1016/j.ejmech.2010.06.024
Ligand and structure based pharmacophore modeling to facilitate novel histone deacetylase 8 inhibitor design
Abstract
Over expression of histone deacetylases (HDACs) leads to the suppression of various gene expressions including cancer suppressor gene. Thus, novel inhibitors of these enzymes can be a valid method to treat cancers. To facilitate the discovery of novel HDAC8 inhibitors, pharmacophore models were generated using ligand and receptor based approaches and validated with a database of active and inactive compounds. These validated pharmacophores have effectively been used in search of three databases and final hits were subjected to molecular docking using GOLD 4.1 program. Hit compounds that scored high GOLD fitness scores and showed interactions with catalytically important residues and metal ions were considered. Finally, three compounds have been reported as novel virtual leads to design potent HDAC8 inhibitors.
Copyright (c) 2010 Elsevier Masson SAS. All rights reserved.
Similar articles
-
Docking-enabled pharmacophore model for histone deacetylase 8 inhibitors and its application in anti-cancer drug discovery.J Mol Graph Model. 2010 Nov;29(3):382-95. doi: 10.1016/j.jmgm.2010.07.007. Epub 2010 Aug 3. J Mol Graph Model. 2010. PMID: 20870437
-
Docking of hydroxamic acids into HDAC1 and HDAC8: a rationalization of activity trends and selectivities.J Chem Inf Model. 2009 Dec;49(12):2774-85. doi: 10.1021/ci900288e. J Chem Inf Model. 2009. PMID: 19947584
-
Design, synthesis and biological evaluation of tyrosine-based hydroxamic acid analogs as novel histone deacetylases (HDACs) inhibitors.Bioorg Med Chem. 2011 Aug 1;19(15):4437-44. doi: 10.1016/j.bmc.2011.06.046. Epub 2011 Jun 21. Bioorg Med Chem. 2011. PMID: 21733698
-
Identification of type-specific anticancer histone deacetylase inhibitors: road to success.Cancer Chemother Pharmacol. 2010 Sep;66(4):625-33. doi: 10.1007/s00280-010-1324-y. Epub 2010 Apr 17. Cancer Chemother Pharmacol. 2010. PMID: 20401613 Review.
-
Histone deacetylase inhibitors: a novel class of anti-cancer agents on its way to the market.Prog Med Chem. 2008;46:205-80. doi: 10.1016/S0079-6468(07)00005-7. Prog Med Chem. 2008. PMID: 18381127 Review. No abstract available.
Cited by
-
Lignin-derived oak phenolics: a theoretical examination of additional potential health benefits of red wine.J Mol Model. 2011 Aug;17(8):1841-5. doi: 10.1007/s00894-010-0893-3. Epub 2010 Nov 16. J Mol Model. 2011. PMID: 21080014
-
Discovery of novel potential selective HDAC8 inhibitors by combine ligand-based, structure-based virtual screening and in-vitro biological evaluation.Sci Rep. 2019 Nov 20;9(1):17174. doi: 10.1038/s41598-019-53376-y. Sci Rep. 2019. PMID: 31748509 Free PMC article.
-
Potent BACE-1 inhibitor design using pharmacophore modeling, in silico screening and molecular docking studies.BMC Bioinformatics. 2011 Feb 15;12 Suppl 1(Suppl 1):S28. doi: 10.1186/1471-2105-12-S1-S28. BMC Bioinformatics. 2011. PMID: 21342558 Free PMC article.
-
Exploration of the binding pocket of histone deacetylases: the design of potent and isoform-selective inhibitors.Turk J Biol. 2017 Dec 18;41(6):901-918. doi: 10.3906/biy-1701-26. eCollection 2017. Turk J Biol. 2017. PMID: 30814855 Free PMC article.
-
Identification of Putative Plant-Based ALR-2 Inhibitors to Treat Diabetic Peripheral Neuropathy.Curr Issues Mol Biol. 2022 Jun 29;44(7):2825-2841. doi: 10.3390/cimb44070194. Curr Issues Mol Biol. 2022. PMID: 35877418 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources